Evidence map›Paper›PMID 40289967›Full record

ReviewCurrent Alzheimer research2025

Metabolic Regulation as a Potential Therapeutic Approach for Alzheimer's Disease.

Jinmiao Zhong, Jiaxin Sun, Bing Zhou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current Alzheimer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jinmiao ZhongSchool of Engineering Medicine, Beihang University, Beijing, China.
Jiaxin SunSchool of Biomedical Science and Medicine Engineering, Beihang University, Beijing, China.
Bing ZhouSchool of Engineering Medicine, Beihang University, Beijing, China.

Funding

Beijing Natural Science Foundation L222080, 7192103Chinese Ministry of Science and Technology, China 2019YFA0508603National Natural Science Foundation of China 82271513, 81971198
6 · The paper itself

Abstract

Lecanemab, a therapeutic antibody designed to target amyloid-beta (Aβ) clearance, has recently been approved by the FDA and introduced in multiple countries, representing a significant milestone in advancing Alzheimer's disease (AD) treatment. However, its limited clinical efficacy underscores the need for further investigation of disease pathogenesis. Emerging evidence suggests that glucose and lipid metabolism dysfunction plays a critical role in AD, with metabolic changes emerging as one of the most significantly altered pathways in the early stage of pathology. These findings highlight the therapeutic potential of targeting metabolic regulation as a strategy to address AD.

Indexed as

Alzheimer DiseaseAnimalsGlucoseHumansLipid MetabolismGlucoseAlzheimer's disease (AD)amyloid-beta.glucose metabolismglycolytic enzymelipid metabolismmitochondrial dysfunction

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.